Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 119.00 | |
5 mg | In stock | $ 297.00 | |
10 mg | In stock | $ 493.00 | |
25 mg | In stock | $ 812.00 | |
50 mg | In stock | $ 1,130.00 | |
100 mg | In stock | $ 1,520.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 343.00 |
Description | AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1]. |
Targets&IC50 | RORγ:7.4(pIC50) |
In vitro | AZD0284 (0.37 μM; 5 days) inhibits IL-17A production in human TH17 cells[1]. AZD0284 reduces polarization of TH17 into pathogenic TH17/1 cells. AZD0284 decreases frequency of single IL-17+cell as well as double positive TH17/1 cells. AZD0284 reduces IL-17A secretion and RNA expression of IL-17A, IL-17F, IL-22 and IL-23R[1][2]. |
Molecular Weight | 524.43 |
Formula | C21H18F6N2O5S |
CAS No. | 2101291-07-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 99 mg/mL (188.77 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AZD-0284 2101291-07-8 Metabolism ROR tract RAR-related orphan receptor AZD0284 IL-17F L-23R Inhibitor plaque respiratory vulgaris production IL-17A TH17 psoriasis IL-22 AZD 0284 inhibit cells inhibitor